A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.

Saved in:
Bibliographic Details
Title: A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.
Authors: Emran AA; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Tseng HY; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Gunatilake D; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Cook SJ; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Ahmed F; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Wang S; Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, Australia., Hersey P; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Gallagher SJ; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Tiffen JC; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. Electronic address: j.tiffen@centenary.org.au.
Source: The Journal of investigative dermatology [J Invest Dermatol] 2021 Sep; Vol. 141 (9), pp. 2238-2249.e12. Date of Electronic Publication: 2021 Mar 26.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-1747
DOI:10.1016/j.jid.2020.12.038